Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Matched sibling donors still provide superior survival outcomes in older patients with AML in second complete remission. a study from the global committee and the acute leukemia working party of the european society for blood and marrow transplantation

View Full Paper
Ask AI
Bookmark
Share

Authors

DWDepei WuIBIgor Wolfgang BlauJBJenny Byrne

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows matched sibling donor transplantation improves survival in older AML patients, suggesting a preferred donor type against haploidentical or unrelated donors.

Key Points

  • Graft-versus-host disease was significantly lower in matched sibling donor recipients than in haploidentical transplants.
  • Overall survival after 1 year was highest for matched sibling donor at 65.7%, compared to haploidentical at 53.7%.
  • Assessment using retrospective data from the European Society for Blood and Marrow Transplantation covered patients in second complete remission.
  • Findings highlight the importance of donor selection, especially underscoring matched sibling donors for older AML patients.

Cite This Study

Wu et al. (2025) studied this question.

synapsesocial.com/papers/69362f3d4fa91c937236d487https://doi.org/10.1182/blood-2025-2528
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Better outcomes with haploidentical than matched sibling donors for adult AML patients allo-transplanted in CR with detectable MRD: A study from the global committee and the ALWP of the EBMT.2025 · 1 citations
  2. 2Comparable outcomes of haploidentical, sibling, and unrelated donor transplantation for adult T-ALL in second remission: a study from the global committee and ALWP of the EBMT2025
  3. 3Old mismatched donors are associated with inferior outcomes after allogeneic hematopoietic stem cell transplantation in myelodysplastic syndrome, but not in Acute Myeloid Leukemia2025
  4. 4Young (35 years) matched sibling donors for allogeneic transplantation with post-transplantation cyclophosphamide in patients with secondary acute myeloid leukemia in first complete remission: A study from the ALWP/EBMT2025
  5. 5T cell replete haploidentical transplantation compared to mismatched unrelated allogeneic transplantation with post-transplantation cyclophosphamide in patients with secondary acute myeloid leukemia in first complete remission: A study from the ALWP/EBMT2025